RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS

被引：0
|
作者：
Raje, N. [1 ]
Bensinger, W. [2 ]
Lebovic, D. [3 ]
Lonial, S. [4 ]
Jagannath, S. [5 ]
Acre-Lara, C. [6 ]
Rosko, A. [7 ]
Harb, W. [8 ]
Bahlis, N. [9 ]
Supko, J. [1 ]
Tamang, D. [10 ]
Jones, S. [10 ]
Wheeler, C. [10 ]
Richardson, P. [11 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Emory Univ, Atlanta, GA 30322 USA
[5] Mt Sinai Hosp, New York, NY 10029 USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Ohio State Univ, Columbus, OH 43210 USA
[8] Horizon Oncol Ctr, Lafayette, IN USA
[9] Tom Baker Canc Clin, Calgary, AB, Canada
[10] Acetylon Pharmaceut Inc, Boston, MA USA
[11] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P279
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [31] Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)
    Niesvizky, Ruben
    Richardson, Paul G.
    Yee, Andrew J.
    Nooka, Ajay K.
    Raab, Marc S.
    Shain, Kenneth H.
    Gabrail, Nashat Y.
    Matous, Jeffrey
    Agarwal, Amit B.
    Hoffman, James
    Madan, Sumit
    Pagel, John M.
    San Miguel, Jesus
    Moreau, Philippe
    Mateos, Maria-Victoria
    Facon, Thierry
    Tamang, David
    Jones, Simon S.
    Markelewicz, Robert J., Jr.
    Wheeler, Catherine
    Trede, Nikolaus S.
    Raje, Noopur
    Terpos, Evangelos
    Bensinger, William I.
    BLOOD, 2016, 128 (22)
  • [32] Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Campana, Frank
    Gao, Lei
    Dubin, Franck
    Wack, Claudine
    Anderson, Kenneth C.
    BLOOD, 2016, 128 (22)
  • [33] Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Htut, Myo
    Gasparetto, Cristina
    Zonder, Jeffrey
    Martin, Thomas G., III
    Scott, Emma C.
    Chen, Janice
    Shemesh, Shay
    Brooks, Christopher L.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    Richardson, Paul G.
    Paba-Prada, Claudia E.
    BLOOD, 2016, 128 (22)
  • [34] Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Ray
    Wang, Jim
    Masterson, Tara
    Nottage, Kerri
    Schecter, Jordan
    Chiu, Christopher
    Khokhar, Nushmia
    Ahmadi, Tahamtan
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E14 - E15
  • [35] A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Hilger, James D.
    Klein, Leonard M.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    BLOOD, 2012, 120 (21)
  • [36] OPROZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (OPOMD) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): INITIAL RESULTS OF A PHASE 1B STUDY (NCT01999335)
    Shah, J.
    Niesvizky, R.
    Stadtmauer, E.
    Rifkin, R. M.
    Berenson, J.
    Berdeja, J.
    Sharman, J.
    Lyons, R.
    Klippel, Z.
    Wong, H.
    Chang, Y. L.
    Usmani, S.
    HAEMATOLOGICA, 2016, 101 : 81 - 81
  • [37] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Stampleman, Laura V.
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    BLOOD, 2014, 124 (21)
  • [38] A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A. B.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Jia, J.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2017, 102 : 169 - 169
  • [39] A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Chanan-Khan, Asher
    Roberts, Andrew W.
    Agarwal, Amit B.
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Cordero, Jaclyn
    Ross, Jeremy
    Munasinghe, Wijith
    Jia, Jia
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo
    Verdugo, Maria
    Harrison, Simon J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E16
  • [40] Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Yee, Andrew
    Laubach, Jacob
    Nooka, Ajay
    O'Donnell, Elizabeth
    Harrington, Cynthia
    Agyemang, Emerentia
    Burke, Jill
    Gammon, Marilyn
    Lively, Kathleen
    Packer, Lisette
    Bishop, James
    Bernstein, Zachary
    Lyons, Rebecca
    Wright, Alexandra
    McVey, Cailin
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S58 - S59
12345